Stocks and Investing
Stocks and Investing
Thu, May 5, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, May 4, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, May 3, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Matteis Maintained (ALNY) at Buy with Decreased Target to $107 on, May 3rd, 2016
Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $120 to $107 on, May 3rd, 2016.
Paul has made no other calls on ALNY in the last 4 months.
There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Paul
- Keay Nakae of "Chardan Capital" Initiated at Strong Buy and Held Target at $93 on, Monday, April 4th, 2016
- Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Decreased Target to $81 on, Friday, March 11th, 2016
- Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $154 on, Wednesday, January 20th, 2016
Contributing Sources